In8Bio (INAB) Operating Leases (2021 - 2026)
In8Bio (INAB) posted Operating Leases of $1.3 million for Q1 2026, down 15.16% sequentially from $1.6 million in Q4 2025, and down 53.41% YoY from $2.8 million in Q1 2025.
In8Bio (INAB) Operating Leases (2021 - 2026) Analysis & Trends
In8Bio has reported Operating Leases for 6 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Operating Leases fell 53.41% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 53.41% YoY) and the FY2025 annual result came in at $1.6 million, down 49.38% from the prior year.
- Operating Leases retreated to $1.3 million in Q1 2026 per INAB's latest filing, from $1.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $3.9 million in Q3 2022 and troughed at $1.3 million in Q2 2022.
- A 5-year average of $2.7 million and a median of $3.1 million in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2026: Operating Leases soared 149.01% in 2023, then slumped 53.41% in 2026.
- Over 5 years, Operating Leases stood at $3.7 million in 2022, then retreated by 22.32% to $2.9 million in 2023, then increased by 8.2% to $3.1 million in 2024, then sank by 49.38% to $1.6 million in 2025, then decreased by 15.16% to $1.3 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $1.3 million, $1.6 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 3.09 Mn |
| Sep 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Sep 30, 2023 | 3.07 Mn |
| Jun 30, 2023 | 3.28 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | 3.67 Mn |
| Sep 30, 2022 | 3.85 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | 1.59 Mn |